Vadastuximab  (Synonyms: Anti-Human CD33 Recombinant Antibody)

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Siglec-3/CD33

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

945  [NCBI]

P20138

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.78 kDa

1436390-63-4

Liquid

Colorless to light yellow

[Vadastuximab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow Cytometry analysis of THP-1 cells labelling Vadastuximab (red) with Vadastuximab Antibody (anti-Vadastuximab) (HY-P99037). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃.Human IgG1 kappa isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Loaded Siglec-3/CD33 Protein, Human (HEK293, Fc-His, HY-P72472) on NTA biosensor, can bind Vadastuximab with an affinity constant of 8.459E-11 M as determined in BLI assay.
• 
  Immobilized Siglec-3/CD33 Protein, Human (HEK293, hFc, HY-P73642) can bind Vadastuximab. The EC₅₀ for this effect is 5.963 ng/mL.

• [1]. Eytan M Stein, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131(4):387-396.  [Content Brief]